eltrombopag

Known as: Eltrombopagum, eltrombopag [Chemical/Ingredient] 
An orally active thrombopoietin receptor agonist with megakaryopoiesis stimulating activity. Eltrombopag binds to and stimulates the platelet… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2006-2018
020406020062018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2015
Review
2015
Aplastic anemia is a rare disorder characterized by suppression of bone marrow function resulting in progressive pancytopenia. A… (More)
  • table 1
  • table 2
Is this relevant?
Highly Cited
2013
Highly Cited
2013
Patients with chronic immune thrombocytopenia may have bleeding resulting from low platelet counts. Eltrombopag increases and… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • table 4
Is this relevant?
Highly Cited
2012
Highly Cited
2012
BACKGROUND Severe aplastic anemia, which is characterized by immune-mediated bone marrow hypoplasia and pancytopenia, can be… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2012
Highly Cited
2012
BACKGROUND Eltrombopag is an oral thrombopoietin-receptor agonist. This study evaluated the efficacy of eltrombopag for… (More)
Is this relevant?
Highly Cited
2011
Highly Cited
2011
BACKGROUND Eltrombopag is an oral thrombopoietin receptor agonist for the treatment of thrombocytopenia. We aimed to compare the… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2010
2010
Platelet transfusion is currently the primary medical treatment for reducing thrombocytopenia in patients with inherited… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Eltrombopag is a first-in-class, orally bioavailable, small-molecule, nonpeptide agonist of the thrombopoietin receptor (TpoR… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 4
  • figure 3
Is this relevant?
Highly Cited
2007
Highly Cited
2007
BACKGROUND The pathogenesis of chronic idiopathic thrombocytopenic purpura (ITP) involves antibody-mediated platelet destruction… (More)
Is this relevant?
Highly Cited
2007
Highly Cited
2007
BACKGROUND Eltrombopag is a new, orally active thrombopoietin-receptor agonist that stimulates thrombopoiesis. We evaluated its… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Eltrombopag (SB-497 115) is a first-in-class, oral, small-molecule, nonpeptide agonist of the thrombopoietin receptor (TpoR… (More)
Is this relevant?